Form 15-12G Repare Therapeutics Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
001-39335
Commission File Number
Repare Therapuetics Inc.
(Exact name of registrant as specified in its charter)
2200 Powell Street, Suite 310
Emeryville, California 94608
(510) 204-7200
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Shares, no par value
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
| Rule 12g-4(a)(1) |
☒ | |
| Rule 12g-4(a)(2) |
☐ | |
| Rule 12h-3(b)(1)(i) |
☒ | |
| Rule 12h-3(b)(1)(ii) |
☐ | |
| Rule 15d-6 |
☐ | |
| Rule 15d-22(b) |
☐ |
Approximate number of holders of record as of the certification or notice date: One
Pursuant to the requirements of the Securities Exchange Act of 1934, Repare Therapeutics Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
| Date: February 19, 2026 | Repare Therapeutics Inc. | |||||
| By: | /s/ Owen Hughes | |||||
| Name: Owen Hughes | ||||||
| Title: Director | ||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exclusive: Nie Ying Drives Standardized Upgrade of InsurTech via Federated Learning and Ethical Governance
- FreeCast Announces Pricing of $23.7 Million Private Placement of Common Stock with New Institutional and Existing Long-Term Investors
- Man Group PLC : Form 8.3 - Senior plc
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share